Markus Warmuth, M.D.

Markus Warmuth, M.D.

Chief Executive OfficeratMonte Rosa Therapeutics· In proxies 2022–2025

Pay in FY2025+106% from the year before · Monte Rosa Therapeutics stock +125.9% the same year

Markus Warmuth, M.D. was paid $5.0M in FY2025 (Dec), up 106%. Monte Rosa Therapeutics stock rose 125.9% that year.

Pay$100 in the stock at the end of FY21 → $77
Pay is from the Summary Compensation Table of each Monte Rosa Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Monte Rosa TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -46%
  2. IMV Inc.Public company · 5 yr
    • Director2018 – 2023 · 5 yrNo stock prices for these years
  3. Relay TherapeuticsPublic company · 1 yr
    • Director2018 – 2019 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?